Joe Chehade, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1124078076
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 57.0% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 57 payments — averaging $64.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Dexcom, Inc.$355
- AstraZeneca$317
- Avion Pharmaceuticals$243
- Abbott$219
- Mannkind Corporation$115
- plus $319 from 8 others
Across 136 payments — averaging $3976.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$432K
- Sanofi US Services Inc.$96K
- Lexicon Pharmaceuticals, Inc.$13K
What the payments were for
- Travel & lodging$1,44940%
- Food & beverage$2,10858%
- Education$923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 25 | $2,080 |
| Dexcom, Inc. | 6 | $355 |
| AstraZeneca | 3 | $317 |
| Avion Pharmaceuticals | 3 | $243 |
| Abbott | 10 | $219 |
| Mannkind Corporation | 1 | $115 |
| Amgen | 1 | $112 |
| Exelixis Inc. | 1 | $87 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Ascensia Diabetes Care US Inc. | 2 | $28 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| Insulet Corporation | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,127
- MINIMED 780G$262
- NP Thyroid 60$150
- Strensiq$126
- AFREZZA$115
- TEPEZZA$112
How this compares
$3,648 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 254 | $268,174 |
| TrulicityDulaglutide | 124 | $144,054 |
| JardianceEmpagliflozin | 105 | $104,442 |
| ForteoTeriparatide | 12 | $59,240 |
| FarxigaDapagliflozin Propanediol | 23 | $20,058 |
| MounjaroTirzepatide | 13 | $15,836 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 51 | $15,034 |
| HumalogInsulin Lispro | 46 | $14,168 |
| JanuviaSitagliptin Phosphate | 13 | $13,050 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $8,262 |
| Humalog Kwikpen U-100Insulin Lispro | 38 | $7,741 |
| Repatha SureclickEvolocumab | 13 | $7,184 |
| NovologInsulin Aspart | 18 | $5,591 |
| SynthroidLevothyroxine Sodium | 45 | $4,437 |
| Novolog FlexpenInsulin Aspart | 32 | $4,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $13 | $273,765272 claims |
| Lilly USA, LLCTrulicity, Forteo, Mounjaro, Humalog | $12 | $233,298195 claims |
| AstraZenecaFarxiga | $317 | $20,05823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Wasim DeebJacksonville$286K
- Khurram WadudJacksonville$77K
- Senan SultanJacksonville$55K
- Firas WardaJacksonville$38K
- Maria Hurtado AndradeJacksonville$36K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.